logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2020
SOLIGENIX, INC.
Final results from phase III study of SGX942 (dusquetide)
Oral mucositis in patients with head and neck cancer
Q4 2020
Catabasis Pharmaceuticals, Inc.
Top-line results from phase III trial of Edasalonexent (POLARIS DMD)
Duchenne muscular dystrophy
Oct 2020
Vaccinex, Inc.
Topline Data from phase II study of VX15/2503 ( SIGNAL)
Early manifest and late prodromal Huntington's disease
Oct 2020
Tracon Pharmaceuticals, Inc.
Completion of Phase 1/2A Study
Metastatic castrate resistant prostate cancer
Q4 2020
RHYTHM PHARMACEUTICALS, INC.
Topline data from phase III trial of Setmelanotide
BBS and Alström syndrome
Q4 2020
PhaseBio Pharmaceuticals Inc
Results from Phase 2b clinical trial of PB1046
Pulmonary Arterial Hypertension
Q4 2020
Syros Pharmaceuticals
Potential proof-of-concept data from additional cohort in Phase 2 trial evaluating safety and efficacy of SY-1425 in combination with azacitidine
RARA or IRF8 biomarker-positive patients with relapsed or refractory AML
Q4 2020
IDEAYA Biosciences
Interim data from phase I/II basket trial of IDE196
Solid tumors harboring GNAQ/11 mutations or PRKC fusions
Q4 2020
BioXcel Therapeutics, Inc.
Initial efficacy data from phase 1b/2 double combination study of BXCL701 and Keytruda
Treatment-emergent neuroendocrine prostate cancer (tNEPC)
Q4 2020
Arcus Biosciences, Inc
Mature Phase 1b data of AB928
Multiple tumor types
Q4 2020
Arcus Biosciences, Inc
Early Phase 2 randomized data of AB928
Multiple tumor types
Q4 2020
Arcus Biosciences, Inc
Randomized data from phase II study of AB154
First-line NSCLC
Q4 2020
Inovio Pharmaceuticals Inc.
Top-line efficacy data from phase III trial of VGX-3100 (REVEAL 1)
Cervical dysplasia caused by human papillomavirus (HPV)
Q4 2020
Inovio Pharmaceuticals Inc.
18-month overall survival data from phase II trial of INO-5401
Glioblastoma multiforme
Q4 2020
Cytokinetics Inc.
Topline data from phase III study of Omecamtiv mecarbil (GALACTIC-HF)
Heart failure
Q4 2020
Can-Fite BioPharma Ltd.
Interim analysis from phase III study of Piclidenoson
Rheumatoid Arthritis
Q4 2020
Syndax Pharma
Results from phase I/II trial of SNDX-6352
Chronic Graft Versus Host Disease
Q4 2020
Syndax Pharma
Additional findings from phase I/II clinical trial of SNDX-5613 ( AUGMENT-101)
Relapsed/refractory acute leukemias
Q4 2020
Immunovant, Inc
Initial results from phase IIa clinical trial of IMVT-1401 ( ASCEND WAHA)
Warm autoimmune hemolytic anemia
Q4 2020
BioXcel Therapeutics, Inc.
Initial data readout from phase Ib/II trial of BXCL701 in combination with KEYTRUDA
Neuroendocrine prostate cancer
Q4 2020
IMARA Inc.
Top-line data from phase IIa clinical trial of IMR-687
Sickle cell disease in adults
Q4 2020
Arena Pharmaceutical Inc.
Topline data from phase 2b ADVISE trial evaluating etrasimod
Atopic dermatitis (AD)
Q4 2020
Arena Pharmaceutical Inc.
Topline data from Phase 2b trial of Olorinab (CAPTIVATE)
Abdominal pain associated with irritable bowel syndrome (IBS-C, IBS-D)
Q4 2020
Arena Pharmaceutical Inc.
Topline data from Phase 1 trial of APD418
Acute heart failure (AHF)
Q4 2020
brainstorm cell therapeutics inc.
Top-line data from phase III pivotal trial of NurOwn
Amyotrophic lateral sclerosis